QQQ   294.43 (-0.06%)
AAPL   143.07 (-0.85%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.31 (+1.99%)
BABA   112.80 (+2.36%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.17 (+0.86%)
DIS   108.54 (+0.05%)
AMC   5.57 (+4.11%)
PFE   43.81 (-0.79%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   143.07 (-0.85%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.31 (+1.99%)
BABA   112.80 (+2.36%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.17 (+0.86%)
DIS   108.54 (+0.05%)
AMC   5.57 (+4.11%)
PFE   43.81 (-0.79%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   143.07 (-0.85%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.31 (+1.99%)
BABA   112.80 (+2.36%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.17 (+0.86%)
DIS   108.54 (+0.05%)
AMC   5.57 (+4.11%)
PFE   43.81 (-0.79%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   143.07 (-0.85%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.31 (+1.99%)
BABA   112.80 (+2.36%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.17 (+0.86%)
DIS   108.54 (+0.05%)
AMC   5.57 (+4.11%)
PFE   43.81 (-0.79%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$15.78
-0.02 (-0.13%)
(As of 02/1/2023 09:47 AM ET)
Add
Compare
Today's Range
$15.67
$15.79
50-Day Range
$14.36
$16.27
52-Week Range
$12.28
$16.30
Volume
164,174 shs
Average Volume
3.17 million shs
Market Capitalization
$48.93 billion
P/E Ratio
29.22
Dividend Yield
3.40%
Price Target
$24.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
51.9% Upside
$24.00 Price Target
Short Interest
Healthy
0.28% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.49mentions of Takeda Pharmaceutical in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

385th out of 1,053 stocks

Pharmaceutical Preparations Industry

189th out of 519 stocks


TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

Top Lithium Stock To Watch
Today's stock market news features a lithium stock with blue sky potential.
Hutchmed shares jump on US$1.13bn Takeda deal
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
Takeda inks deal with Hutchmed for up to $1.1 billion
Takeda Recognized as a Top Employer in Canada in 2023
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Today
2/01/2023
Next Earnings (Estimated)
2/02/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+52.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$2.05 billion
Pretax Margin
5.86%

Debt

Sales & Book Value

Annual Sales
$31.79 billion
Cash Flow
$3.55 per share
Book Value
$16.31 per share

Miscellaneous

Outstanding Shares
3,100,720,000
Free Float
3,099,482,000
Market Cap
$48.93 billion
Optionable
Optionable
Beta
0.65

Social Links


Key Executives

  • Mr. Christophe Weber (Age 57)
    Pres, CEO & Representative Director
    Comp: $4.45M
  • Mr. Constantine Saroukos (Age 52)
    CFO & Representative Director
    Comp: $2.66M
  • Dr. Andrew S. Plump (Age 58)
    Pres of R&D and Representative Director
    Comp: $2.53M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 66)
    Member of Management Board
  • Salvatore Alesci
    Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corp. Controller
  • Mr. Iwaaki Taniguchi
    Sr. VP of Corp. Fin. & Controlling Department
  • Mr. Gabriele Ricci (Age 45)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Fin.













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings
or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

3 analysts have issued 12 month target prices for Takeda Pharmaceutical's shares. Their TAK share price forecasts range from $24.00 to $24.00. On average, they expect the company's stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 51.9% from the stock's current price.
View analysts price targets for TAK
or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2023?

Takeda Pharmaceutical's stock was trading at $15.60 at the start of the year. Since then, TAK stock has increased by 1.3% and is now trading at $15.80.
View the best growth stocks for 2023 here
.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 8,730,000 shares, an increase of 19.3% from the December 31st total of 7,320,000 shares. Based on an average trading volume of 2,880,000 shares, the days-to-cover ratio is currently 3.0 days. Currently, 0.3% of the company's shares are sold short.
View Takeda Pharmaceutical's Short Interest
.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our TAK earnings forecast
.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.54 per share and currently has a dividend yield of 3.37%. The dividend payout ratio is 100.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of $3.80-$3.80 for the period. The company issued revenue guidance of $28.46 billion-$28.46 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Natixis Advisors L.P. (0.02%), Clean Yield Group (0.02%), Manning & Napier Group LLC (0.01%), Sippican Capital Advisors (0.00%), Comerica Bank (0.00%) and Vestmark Advisory Solutions Inc. (0.00%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $15.80.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $48.99 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.54 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 2/1/2023 by MarketBeat.com Staff